Ronald Blue & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Ronald Blue & Co’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,994	Closed	-$262K	–	223
2015 Q4	$262K	Sell	3,994 -9,725	-71%	-$601K	0.01%	141
2015 Q3	$774K	Sell	13,719 -3,767	-22%	-$244K	0.04%	95
2015 Q2	$1.03M	Buy	17,486 +813	+5%	+$50.2K	0.05%	85
2015 Q1	$1.04M	Sell	16,673 -1,118	-6%	-$65K	0.05%	86
2014 Q4	$1.02M	Buy	17,791 +1,910	+12%	+$106K	0.05%	86
2014 Q3	$853K	Buy	15,881 +1,267	+9%	+$67.1K	0.06%	92
2014 Q2	$766K	Buy	14,614 +1,978	+16%	+$101K	0.05%	109
2014 Q1	$668K	Sell	12,636 -549	-4%	-$25.4K	0.05%	117
2013 Q4	$528K	Sell	13,185 -1,582	-11%	-$62.3K	0.04%	144
2013 Q3	$558K	Buy	14,767 +14,312	+3,145%	+$558K	0.05%	112
2013 Q2	$18K	Buy	+455	New	+$17.7K	﹤0.01%	209

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Ronald Blue & Co's TEVA Position: Q1 2016 in Review

Ronald Blue & Co sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 3,994 shares — an estimated $262K sold.

Ronald Blue & Co first reported a position in TEVA in Q2 2013 and held it in 11 quarters. The position peaked at $1.04M in Q1 2015. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

Ronald Blue & Co reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Ronald Blue & Co sold 3,994 Teva Pharmaceuticals shares in Q1 2016, an estimated $262K.
Ronald Blue & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Ronald Blue & Co's Teva Pharmaceuticals position peaked at $1.04M in Q1 2015.
836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on Ronald Blue & Co's 13F filing for Q1 2016, filed 13 May 2016.